# Ancora Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ancora-biotech

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.ancorabiotech.com
- Total disclosed funding: $60M
- Latest round: Series A (Jun 9, 2022)
- Investors on record: 2

## About

Based in California, US, and founded in 2021 by CEO Roland Buelow, Ancora Biotech LLC, a.k.a. Ancora Biotech operates as a biopharmaceutical company that intends to develop antibody biotherapeutics drugs intended to develop a treatment for several life-threatening diseases. In June 2022, Ancora Biotech LLC raised USD 60 million in a Series A funding co-led by Lightspeed Venture Partners and SR One.

The company’s product line includes TeneoTwo’s TNB-486, an antibody biotherapeutic drug in phase I clinical studies for the treatment of B-cell malignancies; TeneoFour’s TNB-738, an antibody biotherapeutic drug in phase I clinical studies for the treatment of metabolic and inflammatory diseases; and TeneoTen’s anti-HBVxCD3, an antibody biotherapeutic drug for the treatment of chronic hepatitis B (CHB).

## Funding rounds

- Series A, Jun 9, 2022, $60M — Lightspeed Venture Partners, SR One

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A